Moleculin Receives Notice of Intent to Grant New Patent for Annamycin
– New patent enhances market position in Europe
HOUSTON — Moleculin Biotech, Inc. (Nasdaq: MBRX) has recently announced significant progress in its intellectual property portfolio. The company, known for its innovative approach towards treating hard-to-treat cancers, has received a Notice of Intent to Grant for a European patent application related to its groundbreaking drug candidate, Annamycin, which is also recognized under its non-proprietary name, naxtarubicin. This patent is poised to fortify Moleculin’s market position in the European Union, potentially paving the way for Annamycin to be the first anthracycline treatment devoid of cardiotoxicity.
The granting of the patent is contingent upon the payment of necessary fees and the satisfactory completion of final amendments and formalities. When finalized, the patent will encompass methods for producing a preliposomal Annamycin lyophilizate characterized by enhanced stability and high purity. This patent is expected to remain valid until 2040, with possible extensions based on the time required for regulatory approvals. Moleculin is dedicated to positioning Annamycin as a pioneering non-cardiotoxic anthracycline suitable for treating various forms of cancer, including acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases (STS lung mets).
Preclinical studies conducted at a prestigious cancer research center indicate that Annamycin may have applications in treating several other cancer types, showcasing its versatility. This innovative chemical entity utilizes a unique lipid-based delivery system, which positions it as a promising candidate for a wide spectrum of cancers. Alongside the anticipated European patent, Moleculin holds multiple patents and has pending applications pertaining to Annamycin internationally, including in the U.S. and China.
Walter Klemp, Chairman and CEO of Moleculin, articulated the significance of this new patent, stating, “Our preliposomal formulation for Annamycin not only enhances the drug’s stability but also establishes a scalable platform for the delivery of lipophilic oncology drugs. The addition of this European patent enhances our intellectual property landscape and reinforces Annamycin’s promising potential.” The company’s current portfolio claims cover methods for creating both preliposomal and liposomal formulations of Annamycin, ensuring robust patent protection across key regions.
Annamycin is currently enjoying Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory AML, along with additional Orphan Drug Designation for STS lung mets. Notably, the European Medicines Agency (EMA) has also recognized Annamycin with Orphan Drug Designation for treating relapsed or refractory AML.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company with a focus on developing therapeutic candidates for hard-to-treat tumors and viral infections. Their flagship program, Annamycin, is a next-generation anthracycline designed to circumvent multidrug resistance mechanisms while avoiding the cardiotoxicity often associated with traditional treatments. Annamycin is currently being tested for its effectiveness against relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
The company is embarking on the MIRACLE Trial (MB-108), a crucial Phase 3 clinical trial that evaluates Annamycin in combination with cytarabine for the treatment of AML. Following a successful Phase 1B/2 study (MB-106), Moleculin believes it has significantly mitigated development risks for Annamycin. Future regulatory submissions will play a vital role in advancing the approval process, where the company aims to continue its engagement with regulatory agencies.
Moreover, Moleculin is advancing WP1066, an immune/transcription modulator targeted towards inhibiting cancer-associated transcription factors while promoting the body’s immune response against tumors. The company is also exploring a portfolio of antimetabolites, including WP1122, aimed at combating pathogenic viruses and some cancer forms.
To learn more, visit www.moleculin.com. Follow them on X, LinkedIn, and Facebook.
Frequently Asked Questions
What is the recent achievement of Moleculin Biotech, Inc.?
Moleculin has received notice of intent to grant a new European patent for Annamycin, enhancing its market position.
What is Annamycin, and what are its key benefits?
Annamycin, also known as naxtarubicin, is a non-cardiotoxic anthracycline designed for challenging cancers, especially AML and STS lung metastases.
How does the new patent impact Moleculin’s development efforts?
The patent supports Moleculin's strategy in securing a strong competitive position in Europe and acknowledges Annamycin's innovative delivery methods.
What are the current designations for Annamycin?
Annamycin has received Fast Track Status and Orphan Drug Designations from both the FDA and EMA for specific cancer treatments.
What other products is Moleculin working on?
The company is also developing WP1066 and WP1122, focusing on immune modulation and antiviral, cancer treatment applications, respectively.
